Pharmacokinetics News and Research

RSS

The term pharmacokinetics is derived from the ancient Greek words “pharmakon” and “kinetikos”, meaning “drug” and “putting in motion” respectively. It is one of the main branches of pharmacology, and refers to the way that the body reacts on and affects a pharmaceutical substance in the body.

Next-generation monoclonal antibody prevents malaria

Researchers investigate the pharmacokinetics and safety of L9LS, a monoclonal antibody to prevent malaria.

9 Aug 2022

The efficacy of honokiol in inhibiting SARS-CoV-2 replication in cell culture

Researchers evaluated the efficacy of honokiol in inhibiting SARS-CoV-2 replication in cell cultures.

2 Aug 2022

Decoy ACE2 receptors broadly neutralize SARS-CoV-2 variants

Researchers review current developments in preclinical studies associated with recombinant ACE2 decoy receptors against coronaviruses.

31 Jul 2022

Novel nanoligomer approach to treat severe COVID-19

Researchers discuss the biodistribution and safety of a novel nanoligomer SBCoV207, which was used to targeted miR-2392 in a murine model.

17 Jul 2022

Novel oral nano-in-micro system provides efficient curcumin delivery to alleviate ulcerative colitis

A new study showed that the newly designed oral nano-in-micro hydrogel delivery platform could be efficiently used to deliver curcumin for the treatment of Ulcerative Colitis.

5 Jul 2022

Patient-derived antibody cocktail active across SARS-CoV-2 variants of concern

In a recent study published in the journal Science Immunology, researchers in the United States described a rare anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) three antibody cocktail IMM-BCP-01.

4 Jul 2022

Kratom: A dangerous or beneficial plant?

A new study summarizes the traditional and modern uses of kratom, as well as its pharmacology, benefits, and adverse health impacts.

23 Jun 2022

Safety and efficacy of tixagevimab–cilgavimab in preventing severe COVID

In a recent study published in the Lancet, researchers evaluated the safety and efficacy of tixagevimab–cilgavimab, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibody (mAb) combination in patients with mild to moderate coronavirus disease 2019 (COVID-19).

8 Jun 2022

Novel approach to drug repurposing incorporates two-stage prediction and machine learning

A new study presents a novel approach to drug repurposing that incorporates two-stage prediction and machine learning.

7 Jun 2022

A polymer-nanoparticle hydrogel to subcutaneously deliver broadly neutralizing antibodies against SARS-CoV-2

Researchers compared the polymer-nanoparticle hydrogel system and standard routes of delivery of broadly neutralizing antibodies against SARS-CoV-2 in a mouse model.

27 May 2022

Repurposed drug clofoctol blocks SARS-CoV-2 replication in mouse study

A new paper presents the results of a mouse study using the repurposed antibacterial drug clofoctol against this virus.

23 May 2022

Insight into sustained-release drug delivery systems

In this interview, News-Medical speaks to Thanh T. Nguyen, a project manager at Innocore Pharmaceuticals, about the mechanisms behind long-acting injectables.

From Thermo Fisher Scientific – Materials Characterization 18 May 2022

Study shows polysaccharides of seaweed and abalone inhibit SARS-CoV-2 in vitro

A new study published in Marine Drugs evaluated the inhibitory effect of three polysaccharides, crude polysaccharide from Hizikia fusiforme (CPHF), crude polysaccharide from Sargassum horneri (CPSH), and crude polysaccharide from abalone viscera (CPAV) on the propagation of SARS-CoV-2 in vitro.

28 Apr 2022

Novel plug-and-play multi-organ chip can be customized to the patient

Engineered tissues have become a critical component for modeling diseases and testing the efficacy and safety of drugs in a human context.

27 Apr 2022

Study examines how race and sex influence tacrolimus pharmacokinetics in kidney transplant recipients

Kidney transplant survival is shorter, on average, in Black recipients compared to white recipients receiving similar treatment.

18 Apr 2022

Drugs targeting DNA damage response pathway show therapeutic potential against advanced solid tumors

Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers -; ATR inhibitor elimusertib and PARP inhibitor AZD5305 -; are safe and clinically beneficial in treating patients with advanced solid tumors.

11 Apr 2022

Study explores phytochemical-based antivirals against SARS-CoV-2 infection

A new study depicted plant-based biologically active antiviral agents that are effective against SARS-CoV-2 infection.

11 Apr 2022

Nanomedicine for treating life-threatening brain tumors

Innovation Center of NanoMedicine (Director General: Prof. Kazunori Kataoka) has announced that Dr. Sabina Quader et al. published a review article focusing on the recent nanomedicines for brain cancers on Advanced Drug Delivery Review in this March.

8 Apr 2022

NYU Langone joins NIH-sponsored program as leading center to discover new targets for autoimmune, inflammatory diseases

NYU Langone Health is joining a new National Institutes of Health (NIH)-sponsored program called Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) as a leading center to discover new targets for therapy in these diseases.

30 Mar 2022

Researchers win NIH grant to treat human brain cancer with a drug previously used on canines

The National Institutes of Health is awarding a $3.8 million grant to John Rossmeisl, the Dr. and Mrs. Dorsey Taylor Mahin Professor of Neurology and Neurosurgery at the Virginia-Maryland College of Veterinary Medicine, and Waldemar Debinski, cancer biology professor at the Wake Forest School of Medicine.

21 Mar 2022